Feedback
Settings

Settings

Goto Application

1. WO2022007134 - USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER

Submit observation
PermaLink
Publication Number WO/2022/007134
Publication Date 13.01.2022
International Application No. PCT/CN2020/109966
International Filing Date 19.08.2020
IPC
A61K 31/7034 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Applicants
  • 诺未科技（北京）有限公司 NEWISH TECHNOLOGY (BEIJING) CO., LTD. [CN]/[CN]
Inventors
  • 孙忠杰 SUN, Zhongjie
  • 王晓芳 WANG, Xiaofang
  • 齐海龙 QI, Hailong
Agents
  • 北京集佳知识产权代理有限公司 UNITALEN ATTORNEYS AT LAW
Priority Data
202010643578.406.07.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER
(FR) UTILISATION D'UN COMPOSÉ OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, DIMÈRE OU TRIMÈRE DE CELUI-CI DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LE TRAITEMENT DU CANCER
(ZH) 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
Abstract
(EN) Provided is the use of a compound of formula I or a pharmaceutically acceptable salt, a dimer or a trimer thereof in the preparation of a drug for treating cancer. By means of verifying the inhibition effect of various tumor cells, the results show that the compound of formula I has a certain inhibition effect on tumor cells, and the IC50 value can reach 40.77μM-182.5μM. In animal experiments, the compound of formula I shows good effects of inhibiting tumor volume.
(FR) L'invention concerne l'utilisation d'un composé de formule I ou d'un sel pharmaceutiquement acceptable, d'un dimère ou d'un trimère de celui-ci dans la préparation d'un médicament pour le traitement du cancer. Par vérification de l'effet d'inhibition de diverses cellules tumorales, les résultats montrent que le composé de formule I a un certain effet d'inhibition sur des cellules tumorales, et la valeur de CI50 peut atteindre 40,77 μΜ-182,5 μΜ. Dans des expériences animales, le composé de formule I présente de bons effets d'inhibition du volume tumoral.
(ZH) 式I化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用。通过对多种肿瘤细胞进行抑制效果的验证，结果表明，式I化合物对于肿瘤细胞存在一定的抑制效果，IC50值可达40.77μM～182.5μM。动物实验中式I化合物表现出了良好的抑制肿瘤体积的作用。
Related patent documents
CN113893256
EP3964217
Latest bibliographic data on file with the International Bureau
# -